Eliza Miranda Ramos, Clara Barreto Ramos, Halex Mairton Barbosa Gomes e Silva, Igor Domingos de Souza, Francisco José Mendes dos Reis, Hugo Miguel Ramos Vieira, Gilberto Gonçalves Facco, Antonio Carlos de Abreu, Pamella Aline Miranda Teodoro, Daniel Castro Lima, Emerson Luiz Lima Araújo , Valter Aragão do Nascimento
Introduction: In the world, the glycotoxic model has been used through the use of ethidium bromide (BE) which involves demyelination with the process of remyelination in the central nervous system (CNS). This experimental method helps to detail the events involved in responding to the finding of remyelination in diseases such as Multiple Sclerosis. Objective: This study aims to assess whether Vitamin D has the potential to alter the gait movement of demyelinated rats with ethidium bromide (BE) through experimental glycotoxic models with the use of ethidium bromide (BE) in order to conjugate knowledge about nerve regeneration and the development of strategies that promote the recovery of nervous tissue. Results: The treatment group with 100.000 IU/week demonstrated a significant difference in gait on hind legs compared to the positive control group in specificities in CPMO and APMA. Conclusion: It was possible to concluded in this study that the treatment with Vitamin D supplementation in rats with lesions in the central nervous system showed a faster functional performance and with a greater grip evidenced in gait in high doses of Vitamin D supplementation, in this case, equivalent to 50.000 IU/week to 100.000 IU/week. Keywords: Ethidium bromide, Multiple Sclerosis, demyelination, Vitamin D, gait.